Drugs Containing Excipient (Inactive Ingredient) GELLAN GUM

« Back to Dashboard

Generic drugs containing GELLAN GUM excipient

Company	Ingredient	NDC	Excipient
Sagent Pharmaceuticals	timolol maleate	25021-008	GELLAN GUM
Dr Reddy's Laboratories Inc	timolol maleate ophthalmic gel forming solution 0.5%	43598-748	GELLAN GUM
Alembic Pharmaceuticals Limited	timolol maleate ophthalmic gel forming solution, 0.25%	46708-545	GELLAN GUM

Last updated: October 20, 2026

Gellan gum is a specialty microbial polysaccharide with a small pharmaceutical market relative to food applications. Its commercial outlook is positive because pharmaceutical customers value suspension stability, low use levels, ionic gelation, and compatibility with oral and ophthalmic formulations. Public companies do not report gellan-gum revenue separately, so the financial trajectory must be assessed through supplier exposure, end-market demand, capacity, pricing, and qualification barriers rather than a verified standalone market-size figure.

Gellan Gum Pharmaceutical Excipient Market Dynamics and Financial Trajectory

What is gellan gum and why is it used in pharmaceuticals?

Gellan gum is a microbial polysaccharide produced by fermentation of Sphingomonas elodea. It is used as a rheology modifier, suspending agent, gelling agent, stabilizer, and controlled-release matrix former.

The main commercial grades are:

Grade characteristic	Formulation relevance
High-acyl gellan gum	Softer, more elastic gels; useful where a less brittle structure is required
Low-acyl gellan gum	Firm, clear gels with stronger ion-mediated gelation
Standardized pharmaceutical grade	Controlled viscosity, microbial limits, heavy-metal limits, and lot-to-lot performance
Food-grade material	Lower cost but may not satisfy pharmaceutical qualification, documentation, or impurity controls

Gellan gum forms gels in the presence of cations, including calcium, potassium, sodium, and magnesium. This permits low-concentration use and can improve the physical stability of liquid medicines. The excipient is particularly relevant to aqueous formulations where conventional cellulose derivatives, carbomers, or xanthan gum do not provide the desired clarity, yield stress, or ion responsiveness.

Common pharmaceutical applications include:

• Oral suspensions and liquid medicines
• Ophthalmic gels and in situ gelling drops
• Nasal and mucosal delivery systems
• Modified-release tablets and matrix systems
• Encapsulation and multiparticulate delivery
• Reconstitution products
• Nutraceutical and medical nutrition formulations

The strongest commercial value is usually generated by customized pharmaceutical grades rather than commodity food-grade gellan gum.

How large is the pharmaceutical gellan gum market?

No major public supplier reports pharmaceutical gellan-gum revenue as a separate line item. Published market-research estimates often combine food, beverage, personal care, pharmaceutical, and biotechnology uses. Those estimates are not directly comparable because they use different definitions of gellan gum, geographic scopes, and inclusion rules.

The pharmaceutical segment is smaller than food and beverage but has a higher average selling price per kilogram. The economics are driven by:

1. Fermentation capacity and yield.
2. Purification requirements.
3. Pharmaceutical documentation.
4. Customer qualification costs.
5. Formulation-specific grades.
6. Supply continuity requirements.

A practical market model is therefore based on segment position rather than an unverified global revenue figure:

Market factor	Pharmaceutical impact
Total volume	Low relative to food use
Unit price	Higher for qualified and customized grades
Customer concentration	High because large formulators qualify few suppliers
Switching cost	High after regulatory filing and process validation
Demand growth	Moderate, supported by liquid and specialty delivery systems
Margin profile	Better than commodity hydrocolloids when documentation and technical service are included
Price sensitivity	Moderate for standard grades; lower for validated formulations
Regulatory risk	Manageable but material when grade, source, or manufacturing site changes

Pharmaceutical demand is unlikely to grow at the rate of the broader food hydrocolloid market. It has a better quality of revenue because customers may remain with a qualified supplier for many years after formulation approval.

What is driving pharmaceutical demand for gellan gum?

Growth in liquid and pediatric medicines

Gellan gum can suspend particles at low concentrations while maintaining acceptable pourability and mouthfeel. This makes it relevant to pediatric, geriatric, and dysphagia-oriented formulations.

Liquid formulations face persistent stability challenges, including sedimentation, caking, redispersion failure, viscosity drift, and preservative compatibility. Gellan gum can address several of these issues through yield-stress behavior and ion-mediated structuring.

Ophthalmic and in situ gel systems

Gellan gum can transition from a low-viscosity liquid to a gel in the presence of electrolytes found in tears. This supports longer ocular residence time while permitting administration as a drop. The technical benefit is most relevant to products requiring improved retention without excessive initial viscosity.

The opportunity is formulation-specific. Gellan gum competes with carbomers, hyaluronic acid, cellulose derivatives, poloxamers, and other in situ gelling systems. Clinical performance, sterilization compatibility, preservative interactions, clarity, and ocular comfort determine adoption.

Controlled-release delivery

Gellan gum can form hydrophilic matrices that slow drug diffusion and alter tablet disintegration. Its usefulness depends on polymer concentration, molecular weight, degree of acylation, particle size, compression conditions, and the drug’s solubility.

This application has a larger intellectual-property component than simple suspension use because the protected asset may be a drug-polymer combination, dosage form, release profile, or manufacturing process.

Demand for clean-label and naturally derived excipients

Gellan gum is fermentation-derived and is often positioned as an alternative to animal-derived gelatin or selected synthetic polymers. The commercial benefit is strongest where a sponsor wants a non-animal, plant-compatible, transparent, or low-dose gelling system.

The term "natural" does not remove pharmaceutical qualification requirements. Manufacturers still need control of microbial impurities, residual substrates, heavy metals, endotoxins where relevant, elemental impurities, and batch consistency.

Who are the main gellan gum suppliers?

CP Kelco has historically been the most visible global supplier of pharmaceutical and high-purity gellan gum, including the Gelrite brand used in pharmaceutical and biotechnology applications. In 2024, Tate & Lyle agreed to acquire CP Kelco from J.M. Huber, creating a larger specialty-food and texture-ingredient platform with exposure to hydrocolloids and fermentation-derived ingredients (Tate & Lyle, 2024).

Other supply comes from Asian fermentation and hydrocolloid producers, including Chinese manufacturers that supply food and industrial grades. Their participation creates a two-tier market:

Supplier tier	Typical position
Established multinational supplier	Strong regulatory files, global quality systems, technical support, higher price
Regional pharmaceutical supplier	Competitive pricing, narrower geographic support, variable documentation depth
Food-grade producer	Lower price, limited pharmaceutical acceptability
Custom manufacturer	Application-specific grades and smaller-volume development support

For drug developers, the relevant competitive question is not only who can produce gellan gum. It is who can support regulatory filings, provide change-control notices, maintain validated specifications, and supply consistent material over the product life cycle.

What is the financial trajectory for gellan gum suppliers?

The financial trajectory is more favorable for qualified pharmaceutical grades than for undifferentiated gellan gum. Revenue growth is likely to come from a combination of volume growth, grade upgrades, formulation wins, and price increases linked to fermentation and purification costs.

Cost structure

Major cost inputs include:

• Carbon sources used in fermentation
• Nitrogen and mineral nutrients
• Electricity and steam
• Water and wastewater treatment
• Filtration and purification
• Drying and milling
• Quality testing
• Regulatory documentation
• Packaging and freight

Fermentation creates operating leverage when plant utilization rises. Underutilized capacity can materially weaken margins because fixed bioreactor, downstream-processing, and quality costs are spread over fewer kilograms.

Margin segmentation

Product position	Expected financial profile
Commodity food-grade gellan gum	High price competition and limited switching costs
Standard pharmaceutical grade	Better price realization and stronger retention
Sterile or highly controlled grade	Higher qualification burden and potentially higher margin
Custom grade or formulation service	Highest technical value, but smaller volumes and greater development cost

Tate & Lyle's acquisition of CP Kelco increases the strategic value of gellan gum as part of a broader specialty-ingredient portfolio. Public financial reporting is unlikely to disclose gellan gum as a standalone business. Investors should instead monitor specialty-ingredient revenue, adjusted EBITDA, pricing, volume, capacity utilization, and acquisition synergies in the relevant reporting segment.

What patent protection covers gellan gum?

Gellan gum itself is not a newly emerging active pharmaceutical ingredient with a conventional exclusivity period. Its core composition and commercial use are mature. Broad composition-level exclusivity is therefore limited compared with a new drug molecule.

Patent protection may still apply to:

• Specific low-acyl or high-acyl compositions
• Purification or deacylation processes
• Molecular-weight distributions
• Crosslinked or ionically modified gels
• Drug-polymer controlled-release systems
• Ophthalmic in situ gel formulations
• Nasal or mucosal delivery systems
• Combination excipient systems
• Manufacturing and drying methods

The enforceable commercial asset is usually the drug formulation or delivery system, not the basic excipient. Patent terms depend on the jurisdiction, filing date, priority claims, patent-term adjustment, patent-term extension, and claim scope.

Is gellan gum listed in the FDA Inactive Ingredient Database?

Gellan gum has established pharmaceutical and food regulatory use, and FDA regulatory treatment depends on the route, dosage form, concentration, and specific grade. The FDA Inactive Ingredient Database is the principal public reference for identifying prior approved use by dosage form and route (U.S. Food and Drug Administration, n.d.-a).

A sponsor should distinguish among:

1. Presence in the FDA Inactive Ingredient Database.
2. Compliance with an applicable United States Pharmacopeia monograph.
3. Food-use authorization or GRAS status.
4. Acceptance of a particular pharmaceutical grade.
5. Suitability for a new route or concentration.

A database listing does not automatically validate every supplier or every proposed concentration. Changes in source, manufacturing site, impurity profile, degree of acylation, or molecular-weight distribution can trigger comparability and regulatory review.

Gellan gum is also recognized in international food-additive standards. The Joint FAO/WHO Expert Committee on Food Additives identifies gellan gum as food additive INS 418, but food authorization is not equivalent to approval for a pharmaceutical application (FAO/WHO, n.d.).

When does gellan gum lose exclusivity?

Gellan gum has no single pharmaceutical patent-expiration date comparable to a branded drug. Its underlying composition is commercially mature, and suppliers generally compete through manufacturing know-how, quality systems, customer qualification, and formulation-specific intellectual property.

There is no standard Orange Book exclusivity period for gellan gum as an excipient. The FDA Orange Book identifies approved drug products and patent or exclusivity information associated with those products, not a general monopoly over an excipient (U.S. Food and Drug Administration, n.d.-b).

Paragraph IV challenges are relevant only when a generic applicant challenges patents listed for a drug product that uses gellan gum. The excipient itself is not the normal target of a Paragraph IV certification.

What generic-entry risks exist for gellan gum-containing products?

Generic entry risk depends on the protected drug product, not simply on the presence of gellan gum.

Lower-risk situations

• Gellan gum is used only as a conventional suspending agent.
• No formulation patent claims the polymer system.
• The product has multiple established excipient alternatives.
• The innovator has limited patent coverage beyond the active ingredient.
• The generic can demonstrate bioequivalence using a conventional pathway.

Higher-risk situations

• The formulation depends on a specific gellan-gum concentration or acylation profile.
• The product uses an in situ gel mechanism.
• Release performance depends on polymer molecular weight or ionic interaction.
• The patent claims a specific drug-gellan gum combination.
• The formulation is ophthalmic, nasal, or otherwise sensitive to physical performance.
• Supplier qualification creates a manufacturing barrier.

For generic manufacturers, the main barrier is often reproducibility rather than the cost of the raw material. A technically acceptable substitute may still produce different sedimentation, viscosity, gel strength, dissolution, or ocular residence-time results.

How strong is the gellan gum supply and manufacturing moat?

The supply moat is moderate for basic material and stronger for pharmaceutical-grade material.

Manufacturing barriers

Gellan gum production requires controlled fermentation followed by recovery and purification. Key technical variables include microbial strain, fermentation conditions, broth rheology, deacylation, precipitation, drying, milling, and packaging.

The most difficult parameters to replicate consistently are often:

• Molecular-weight distribution
• Acylation profile
• Gel strength
• Viscosity at defined shear rates
• Ionic sensitivity
• Microbial and endotoxin controls
• Batch-to-batch dissolution behavior

A purchaser may qualify a supplier for one application but reject the same material for another route. This limits the practical substitutability of nominally equivalent grades.

Geographic coverage

Global pharmaceutical customers generally prefer suppliers with:

• Multiple regional distribution points
• Qualified backup manufacturing
• Strong change-control procedures
• Pharmacopoeial documentation
• Auditable quality systems
• Technical support in North America, Europe, and Asia

Asian supply is important for cost competition, but regulatory acceptance depends on the depth of the supplier's quality package and the sponsor's qualification work.

How does gellan gum compare with competing pharmaceutical excipients?

Excipient	Main advantage	Main limitation
Gellan gum	Low-dose gelation, suspension stability, ionic responsiveness	Sensitive to ions and grade variability
Xanthan gum	Strong suspension and pseudoplastic behavior	May create higher viscosity and sensory issues
Carbomer	High thickening efficiency and clear gels	Sensitive to pH, electrolytes, and neutralization
HPMC	Broad regulatory familiarity and controlled-release utility	Less responsive to ionic gelation
Sodium alginate	Ionic gelation and natural origin	Greater variability and ion sensitivity
Hyaluronic acid	Mucoadhesion and biocompatibility	Higher cost and stability constraints
Poloxamer	Thermoresponsive systems	Different gelation profile and formulation limits

Gellan gum is most competitive where transparency, low use level, suspension performance, and ion-triggered gelation matter. It is less attractive where a low-cost, broadly familiar cellulose derivative meets the product requirements.

What is the commercial outlook for gellan gum?

The base-case outlook is moderate growth with improving value mix. Pharmaceutical demand should expand through specialty oral liquids, ophthalmic delivery, modified-release systems, and formulation reformulation. Revenue growth will likely exceed volume growth when customers move from food-grade or standard material to qualified pharmaceutical grades.

The principal risks are:

• Consolidation of supply into fewer producers
• Fermentation and energy-cost inflation
• Long customer qualification cycles
• Substitution by carbomers, HPMC, xanthan gum, or alginates
• Regulatory delays for new routes
• Limited disclosure of pharmaceutical segment revenue
• Dependence on a small number of high-value formulations

The strongest financial positions belong to suppliers that combine fermentation scale with pharmaceutical documentation and application development. Commodity capacity alone is less defensible.

Key Takeaways

• Gellan gum is a specialty microbial polysaccharide used in suspensions, gels, ophthalmic systems, and controlled-release formulations.
• The pharmaceutical market is smaller than the food market but has higher value per kilogram and stronger customer retention.
• Public companies generally do not disclose gellan-gum revenue separately.
• CP Kelco, now part of Tate & Lyle following the 2024 acquisition agreement, is a prominent supplier of high-purity gellan gum.
• The main commercial moat is qualification, consistency, documentation, and technical support rather than broad composition patent protection.
• There is no standalone Orange Book exclusivity period or universal patent-expiration date for gellan gum.
• Generic-entry risk arises from formulation and drug-product patents, not from the basic excipient.
• Financial performance is most attractive in customized pharmaceutical grades and technically demanding delivery systems.

FAQs

Is gellan gum suitable for injectable drugs?

Gellan gum is primarily associated with oral, ophthalmic, mucosal, and controlled-release applications. Injectable use requires route-specific toxicology, sterility, endotoxin, particulate, and compatibility data and cannot be inferred from food or oral use.

What is the difference between Gelrite and generic gellan gum?

Gelrite is a commercial brand associated with CP Kelco's gellan-gum products. Generic gellan gum may differ in molecular weight, acylation, gel strength, viscosity, impurity profile, and regulatory documentation.

Can gellan gum replace HPMC in a controlled-release tablet?

It can replace HPMC in selected formulations, but the polymers are not automatically equivalent. Dissolution, swelling, erosion, compression, drug solubility, and release kinetics must be re-established.

Does gellan gum require a drug master file?

A drug master file may be used where the supplier wants to protect confidential manufacturing information while supporting a customer's regulatory filing. The need depends on the jurisdiction, customer strategy, grade, and regulatory submission.

Is gellan gum vulnerable to supply disruption?

The risk is higher than for widely manufactured cellulose excipients because pharmaceutical-grade production is concentrated and fermentation capacity is specialized. Sponsors reduce exposure through dual sourcing, reserve inventory, change-control agreements, and validated alternative grades.

References

1. Food and Agriculture Organization of the United Nations & World Health Organization. (n.d.). Gellan gum, INS 418: Joint FAO/WHO Expert Committee on Food Additives specifications.
2. Tate & Lyle. (2024). Tate & Lyle to acquire CP Kelco from J.M. Huber Corporation. Tate & Lyle plc.
3. U.S. Food and Drug Administration. (n.d.-a). Inactive Ingredient Database.
4. U.S. Food and Drug Administration. (n.d.-b). Approved drug products with therapeutic equivalence evaluations: Orange Book.
5. United States Pharmacopeial Convention. (n.d.). United States Pharmacopeia-National Formulary: Gellan gum monograph.